Failed drug tests hit AstraZeneca earnings
Pharmaceutical giant AstraZeneca has warned earnings will come in at the lower end of expectations after it took a $381.5m hit from failed drug tests.
Pharmaceutical giant AstraZeneca has warned earnings will come in at the lower end of expectations after it took a $381.5m hit from failed drug tests.
The company has stopped development of its ovarian cancer treatment olaparib and also said its antidepressant compound TC-5214 had not met targets.
As a result, AstraZeneca will take pre-tax impairment charges totalling $381.5m to R&D expense in the fourth quarter of 2011, it said.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
These impairments would push down the company's core earnings per share by around $0.21 in the fourth quarter, it said.
This meant that while full year core EPS would remain in the predicted range of $7.20 to $7.40, earnings were likely to be in the lower half of this scale.
The company is taking an impairment of $285m pre-tax charge due to the failure of olaparib, with a further $96.5m hit based on the lower probability of success for the remaining TC-5214 studies.
Shares in AstraZeneca fell 2% in early trading following the announcement.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
How much should I have in emergency savings?
When your boiler breaks or your car won’t start, you can find yourself paying a hefty bill. How much should you have in emergency savings to cover unexpected costs?
By Katie Williams Published
-
ISA investments by age: should I invest more in my stocks and shares ISA?
Stocks and shares ISAs are a great way to grow long-term wealth, but are they overlooked compared to cash savings? We look at the average ISA investment by age and if you should have more.
By Dan McEvoy Published